Skip to main content
. 2022 Feb 20;14(4):1067. doi: 10.3390/cancers14041067

Figure 6.

Figure 6

CUDC-907 inhibits PI3K/AKT pathway: (A) Gene expression analysis of PIK3C2A, AKT1, MTOR, TBK1, and MYCN in response to CUDC-907 treatments in SH-SY5Y cells. * p < 0.05, ** p < 0.01, and *** p < 0.001. (B) Western blot analysis of different PI3K pathway proteins in response to increasing concentrations of CUDC-907 treatments. CyPB was used as a loading control. Full blots and densitometric data are available in Supplementary Figure S2.